OBJECTIVES: Chronic thromboembolic pulmonary hypertension is due to partial obstruction of the pulmonary arterial bed and may resolve after pulmonary thromboendarterectomy. Persistent pulmonary hypertension, the main complication after pulmonary thromboendarterectomy, may reflect vessel alterations induced by high flow in unobstructed lung territories. The aim of this study was to determine whether correcting high flow led to reversal of the vasculopathy in piglets. METHODS: The effects of high pulmonary blood flow were investigated 5 weeks after creation of an aortopulmonary shunt (n = 10), and reversibility of vessel disease was evaluated at 1 week (n = 10) and 5 weeks after shunt closure (n = 10), compared to sham-operated animals (n = 10). Hemodynamic variables, pulmonary artery reactivity, and morphometry were recorded. We also investigated the endothelin, angiopoietin, and nitric oxide synthase pathways. RESULTS: High flow increased medial thickness in distal pulmonary arteries (55.6% +/- 1.2% vs 35.9% +/- 0.8%; P < .0001) owing to an increase of smooth muscle cell proliferation (proliferating cell nuclear antigen labeling). The endothelium-dependent relaxation was altered (P < .05). This phenomenon was associated to an overexpression of endothelin-1, endothelin-A, angiopoietin 1, angiopoietin 2, and Tie-2 (P < .05). After 1 week of shunt closure, all overexpressed genes returned to control values, the proliferation of smooth muscle cells stopped, and smooth muscle cell apoptosis increased (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling), preceding the normalization of the wall thickness hypertrophy and the pulmonary artery vasoreactivity observed at 5 weeks after shunt closure. CONCLUSION: These results demonstrate that endothelin-1 and angiopoietin pathways are involved in vasculopathy development and may be important therapeutic targets for preventing persistent pulmonary hypertension after pulmonary thromboendarterectomy.
OBJECTIVES:Chronic thromboembolic pulmonary hypertension is due to partial obstruction of the pulmonary arterial bed and may resolve after pulmonary thromboendarterectomy. Persistent pulmonary hypertension, the main complication after pulmonary thromboendarterectomy, may reflect vessel alterations induced by high flow in unobstructed lung territories. The aim of this study was to determine whether correcting high flow led to reversal of the vasculopathy in piglets. METHODS: The effects of high pulmonary blood flow were investigated 5 weeks after creation of an aortopulmonary shunt (n = 10), and reversibility of vessel disease was evaluated at 1 week (n = 10) and 5 weeks after shunt closure (n = 10), compared to sham-operated animals (n = 10). Hemodynamic variables, pulmonary artery reactivity, and morphometry were recorded. We also investigated the endothelin, angiopoietin, and nitric oxide synthase pathways. RESULTS: High flow increased medial thickness in distal pulmonary arteries (55.6% +/- 1.2% vs 35.9% +/- 0.8%; P < .0001) owing to an increase of smooth muscle cell proliferation (proliferating cell nuclear antigen labeling). The endothelium-dependent relaxation was altered (P < .05). This phenomenon was associated to an overexpression of endothelin-1, endothelin-A, angiopoietin 1, angiopoietin 2, and Tie-2 (P < .05). After 1 week of shunt closure, all overexpressed genes returned to control values, the proliferation of smooth muscle cells stopped, and smooth muscle cell apoptosis increased (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling), preceding the normalization of the wall thickness hypertrophy and the pulmonary artery vasoreactivity observed at 5 weeks after shunt closure. CONCLUSION: These results demonstrate that endothelin-1 and angiopoietin pathways are involved in vasculopathy development and may be important therapeutic targets for preventing persistent pulmonary hypertension after pulmonary thromboendarterectomy.
Authors: Jing Tian; Sohrab Fratz; Yali Hou; Qing Lu; Agnes Görlach; John Hess; Christian Schreiber; Sanjeev A Datar; Peter Oishi; John Nechtman; Robert Podolsky; Jin-Xiong She; Jeffrey R Fineman; Stephen M Black Journal: Physiol Genomics Date: 2010-10-26 Impact factor: 3.107
Authors: Diederik E van der Feen; Guido P L Bossers; Quint A J Hagdorn; Jan-Renier Moonen; Kondababu Kurakula; Robert Szulcek; James Chappell; Francesco Vallania; Michele Donato; Klaas Kok; Jaskaren S Kohli; Arjen H Petersen; Tom van Leusden; Marco Demaria; Marie-José T H Goumans; Rudolf A De Boer; Purvesh Khatri; Marlene Rabinovitch; Rolf M F Berger; Beatrijs Bartelds Journal: Sci Transl Med Date: 2020-07-29 Impact factor: 17.956
Authors: Mário Santos; David Systrom; Stephen E Epstein; Anitha John; George Ruiz; Michael J Landzberg; Alexander R Opotowsky Journal: Pulm Circ Date: 2014-12 Impact factor: 3.017
Authors: Sanjiv Kumar; Peter E Oishi; Ruslan Rafikov; Saurabh Aggarwal; Yali Hou; Sanjeev A Datar; Shruti Sharma; Anthony Azakie; Jeffrey R Fineman; Stephen M Black Journal: J Cell Biochem Date: 2013-02 Impact factor: 4.429
Authors: Olaf Mercier; Adriano Tivane; Peter Dorfmüller; Marc de Perrot; François Raoux; Benoît Decante; Saadia Eddahibi; Philippe Dartevelle; Elie Fadel Journal: Pulm Circ Date: 2013-12 Impact factor: 3.017